The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index; 10 of the 13 sources its claims cite were checked for support.
Suspected cholinergic toxicity due to cevimeline hydrochloride and Bacopa monnieri interaction: a case report
Open accessAbstract
Background: Muscarinic agonists are indicated for the treatment of many conditions including ileus, urinary retention, glaucoma, and Sjögren’s syndrome. Due to their lack of tissue specificity, these drugs can lead to undesirable side effects at off-target sites and may be potentiated by supplements that impact the half-life of these drugs. Case presentation: A 58-year-old Caucasian female with history of Sjögren’s syndrome, who was being managed with cevimeline, presented to the primary care office with reported hyperhidrosis, malaise, nausea, and tachycardia. She reported taking an herbal supplement containing B. monnieri and phosphatidylserine the previous night. It has been previously demonstrated that B. monnieri alters cytochrome P450 enzymes. Electrocardiogram showed no acute ST–T changes. Clinical improvement occurred with hydration and discontinuation of the supplement. Conclusions: To our knowledge, there has only been one other documented cevimeline overdose, and it was not associated with an herbal supplementation interaction. Physicians should actively elicit herbal supplement information from patients to anticipate possible drug–herb interactions. An additional consideration of clinical relevance is the known genetic variability that may affect drug responsiveness due to differences in metabolism and half-life of drugs that arise from common genetic variants of cytochrome P450 genes.
Overview
CoChat Summary
TL;DR
A 58-year-old woman with Sjögren’s syndrome on cevimeline developed acute tachycardia, hyperhidrosis, malaise, nausea, and tenesmus within 30 minutes of taking a Bacopa monnieri/phosphatidylserine supplement; symptoms resolved with hydration and supplement discontinuation. The authors hypothesize a drug–herb interaction via B. monnieri inhibition of CYP3A4/CYP2D6, which metabolize cevimeline, causing suspected cholinergic toxicity.
Key findings
- The patient was a 58-year-old Caucasian female with Sjögren’s syndrome and subacute cutaneous lupus erythematosus, prescribed cevimeline 30 mg three times daily and hydroxychloroquine 150 mg daily.
- After taking her usual 30 mg cevimeline plus two gummy tablets of a B. monnieri- and phosphatidylserine-containing supplement, she reported acute onset within 30 minutes of tachycardia, hyperhidrosis, malaise, nausea, and tenesmus.
- Physical exam showed blood pressure 127/77, pulse oximetry 94% on room air, and ECG with no acute ST–T changes and normal heart rate of 83; symptoms subsided after hydration and supplement discontinuation.
- The authors note B. monnieri acts as a competitive inhibitor of CYP3A4 and a weak inhibitor of CYP2D6 in vitro, while cevimeline is metabolized primarily by CYP2D6, CYP3A3, and CYP3A4, supporting a hypothesized interaction.
Methods
- Single case report of one patient presenting to primary care with suspected cholinergic toxicity after cevimeline and an herbal supplement.
- Data included clinical history, physical examination, ECG, and telephone follow-up; no laboratory drug levels or genetic testing were reported.
- Main analysis is descriptive and hypothesis-generating, linking the patient’s symptoms to possible CYP-mediated elevation of cevimeline due to B. monnieri.
Limitations
- The paper states there was a lack of detailed information on the supplement’s composition and that a definitive causal link between symptom onset and the B. monnieri-containing supplement cannot be established.
- The paper also notes the patient’s CYP metabolic profile was unknown and not standard.
- Evident from the text: this is a single case with no measured cevimeline concentrations, no CYP genotype, and no rechallenge, so the proposed drug–herb interaction remains suspected rather than confirmed.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
8 Valid · 1 Not valid · 3 Not checked · 13 Own results and interpretations
Every source the paper cites for this claim was checked and supports it.
In the paper
“B. monnieri has been studied as an acetylcholinesterase inhibitor in animal and in vitro models [7].”
§ Suspected cholinergic toxicity due to cevimeline hydrochloride and Bacopa monnieri interaction: a case report > Background
What the sources say
- Supportedcites [7] Aguiar S, Borowski T. Neuropharmacological review of the nootropic herb Bacopa monnieri. Rejuvenation Res. 2013;16(4):313–26. source
The Introduction describes a mouse amnesia study of Bacopa monnieri and reports that the extract also showed dose-dependent acetylcholinesterase inhibition in vitro. The review therefore supports the claim that it has been studied in animal and in vitro models. (LLM, conf=0.92)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Of note, patients may not disclose use of herbal supplements to their clinicians.”
§ Suspected cholinergic toxicity due to cevimeline hydrochloride and Bacopa monnieri interaction: a case report > Discussion
What the sources say
- Supportedcites [14] Mehta DH, Gardiner PM, Phillips RS, McCarthy EP. Herbal and dietary supplement disclosure to health care providers by individuals with chronic conditions. J Altern Complement Med. 2008;14(10):1263–9. source
The Abstract Results report that only 33% of herbal and dietary supplement users disclosed their use to a conventional health care provider. The Discussion likewise says only one in three adults reported disclosing their use, directly supporting the claim that patients may not tell clinicians about herbal supplements. (LLM, conf=0.95)
hedged- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“It has been previously demonstrated that B. monnieri alters cytochrome P450 enzymes.”
§ Suspected cholinergic toxicity due to cevimeline hydrochloride and Bacopa monnieri interaction: a case report > Abstract > Case presentation
What the sources say
- Supportedcites [10] Ramasamy S, Kiew LV, Chung LY. Inhibition of human cytochrome P450 enzymes by Bacopa monnieri standardized extract and constituents. Molecules. 2014;19(2):2588–601. source
The Conclusions (Section 5) state that B. monnieri standardized extract inhibited several CYP enzymes. The claim is a broad paraphrase of that finding; the study tested enzyme activity in vitro, not effects in people. (LLM, conf=0.93)
boostedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“Cevimeline is metabolized primarily by the hepatic isozymes CYP2D6, CYP3A3, and CYP3A4 [11].”
§ Suspected cholinergic toxicity due to cevimeline hydrochloride and Bacopa monnieri interaction: a case report > Discussion
What the sources say
- Could not verifycites [11] Whirl-Carrillo M, Huddart R, Gong L, et al. An evidence-based framework for evaluating pharmacogenomics knowledge for personalized medicine. Clin Pharmacol Ther. 2021;110(3):563–72. sourceExperimental — accuracy not yet measured
The Clinical annotations creation section discusses how PharmGKB summarizes gene–drug associations, not cevimeline metabolism. Searches for cevimeline with CYP2D6, CYP3A3, and CYP3A4, and for hepatic metabolism by these enzymes, found no passage in our copy addressing the claim; page numbers were not provided. (LLM, conf=0.76)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Clinical improvement occurred with hydration and discontinuation of the supplement.”
§ Suspected cholinergic toxicity due to cevimeline hydrochloride and Bacopa monnieri interaction: a case report > Abstract > Case presentation
plainstates a causeSingle case- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
3 more claims
Create a free account to see all 25 claims and every source verdict.
- It may state two separate claims as one. 13
- Probably not a substantial claim. 9
- The quote only partly states this claim. 1
Citations
Cites
An Evidence‐Based Framework for Evaluating Pharmacogenomics Knowledge for Personalized Medicine
Whirl‐Carrillo, M., Huddart, R., Gong, L., Sangkuhl, K., Thorn, C. F., Whaley, R., & Klein, T. E. (2021) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.2350 · Cited by 810 · cited 2×
“Cevimeline is metabolized primarily by the hepatic isozymes CYP2D6, CYP3A3, and CYP3A4 [11].”
BackgroundHarmless Herbs? A Review of the Recent Literature
Ernst, E. (1998) · The American Journal of Medicine · doi:10.1016/s0002-9343(97)00397-5 · Cited by 634 · cited 1×
“Herbal supplements may be viewed by patients as “natural” and therefore without harm to the patient [13].”
BackgroundThe epidemiology of Sjögren’s syndrome
Shahane, A., & Patel, R. (2014) · Clinical Epidemiology · doi:10.2147/clep.s47399 · Cited by 354
Neuropharmacological Review of the Nootropic Herb Bacopa monnieri
Aguiar, S., & Borowski, T. (2013) · Rejuvenation Research · doi:10.1089/rej.2013.1431 · Cited by 295 · cited 2×
“monnieri has been studied as an acetylcholinesterase inhibitor in animal and in vitro models [7].”
BackgroundShelley, B. M., Sussman, A. L., Williams, R. L., Segal, A. R., Crabtree, B. F., & Clinicians, O. B. O. T. R. N. (2009) · The Annals of Family Medicine · doi:10.1370/afm.947 · Cited by 258 · cited 1×
“Importantly, improved communication between providers and their patients regarding herbal medication usage could help anticipate possible drug–herb interactions [15].”
BackgroundA new molecular classification to drive precision treatment strategies in primary Sjögren’s syndrome
Soret, P., Le Dantec, C., Desvaux, E., Foulquier, N., Chassagnol, B., Hubert, S., Jamin, C., Barturen, G., Desachy, G., Devauchelle-Pensec, V., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-23472-7 · Cited by 173 · cited 2×
“Like other complex autoimmune disorders, evidence suggests multifactorial origins including pathogenic variants or epigenetic modifiers of class I and more significantly class II human leukocyte antigens (HLAs), displaying ethnic heterogeneity [4].”
BackgroundCurrent concepts on Sjögren's syndrome – classification criteria and biomarkers
Jonsson, R., Brokstad, K. A., Jonsson, M. V., Delaleu, N., & Skarstein, K. (2018) · European Journal of Oral Sciences · doi:10.1111/eos.12536 · Cited by 162
Mehta, D. H., Gardiner, P. M., Phillips, R. S., & McCarthy, E. P. (2008) · The Journal of Alternative and Complementary Medicine · doi:10.1089/acm.2008.0290 · Cited by 140 · cited 1×
“Although they reported that individuals with chronic medical conditions who access healthcare more frequently and who are managed with prescription drugs have a higher likelihood of disclosure, the rate is still less than 50% [14].”
BackgroundThe role of Epstein–Barr virus infection in primary Sjögren's syndrome
Maślińska, M. (2019) · Current Opinion in Rheumatology · doi:10.1097/bor.0000000000000622 · Cited by 72 · cited 1×
“The etiology of SjS is unknown, but several factors, including detection of Epstein–Barr virus in salivary glands, has been implicated in the autoimmune response [3].”
BackgroundToxicity of Herbs, Vitamins, and Supplements
Charen, E., & Harbord, N. B. (2020) · Advances in Chronic Kidney Disease · doi:10.1053/j.ackd.2019.08.003 · Cited by 70 · cited 4×
“Abbreviations SjS: Sjögren’s syndrome; CNS: Central nervous system; ECG: Electrocardiogram; CYP: Cytochrome; FDA: Food and Drug Administration.”
BackgroundInfluential
Research works printed but not linked: 1
- Patel R, Shahane A. The epidemiology of Sjogren’s syndrome. Clin Epidemiol. 2014;6:247–55.
Cited by
Gościniak, A., Stasiłowicz-Krzemień, A., Szeląg, M., Pawlak, J., Skiera, I., Kwiatkowska, H., Nowak, N., Bernady, K., Trzaskoma, P., Zimak-Krótkopad, O., et al. (2025) · Nutrients · doi:10.3390/nu17111939 · Cited by 44
“During the study, as in the previously cited ones, several cases of gastrointestinal disturbances were found, including vomiting and upset stomach lasting about three days, after which no further side effects were observed [60,61].”
Siwek, M., Woroń, J., Wrzosek, A., Gupało, J., & Chrobak, A. A. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1271776 · Cited by 37
“Clinical improvement has been shown after discontinuation of the supplement (Acquarulo et al., 2022).”
BackgroundSafety Considerations for Natural Products with Adaptogenic and Immunomodulating Activities
Liang, C., Woerdenbag, H. J., Ekhart, C., Vitalone, A., & van Hunsel, F. P. A. M. (2025) · Pharmaceuticals · doi:10.3390/ph18081208 · Cited by 18
“Reported symptoms included hyperhidrosis, nausea, dizziness, and tachycardia [130].”
The Role of Bacopa monnieri in Alzheimer’s Disease: Mechanisms and Potential Clinical Use—A Review
Wiciński, M., Fajkiel-Madajczyk, A., Wójcicki, J., Ozorowski, M., & Szambelan, M. (2025) · Nutrients · doi:10.3390/nu17223538 · Cited by 10
“After discontinuing the supplement, the patient’s condition improved [42].”
Paul, P., Majumdar, S., Basu, A., Jha, S., & Halder, M. (2025) · Springer eBooks · doi:10.1007/978-3-642-36202-6_157-1 · Cited by 6
Metadata
- Authors
- Acquarulo, B., Tandon, P., & Macica, C. M.
- Affiliations
- Quinnipiac University (US)
- Corresponding author
- Macica, Carolyn M.
- ORCID
- Macica, Carolyn M.
- Venue
- Journal of Medical Case Reports
- Published
- 2022-06-29
- Volume
- 16
- Issue
- 1
- Pages
- 253-253
- ISSN
- 1752-1947 (ISSN-L)
- PMC
- PMC9241182
- OpenAlex
- W4283705211
- Semantic Scholar
- 81dfde131bdc4a9bef92a7168f647201100ce4d7
- Cited by
- 8
- References
- 15
- Citations by year
- 2026: 1 · 2025: 4 · 2024: 2 · 2023: 1
- FWCI
- 1.73
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Journal of Medical Case Reports (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Complementary and alternative medicine › Complementary and Alternative Medicine Studies
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
- Health Sciences › Medicine › Emergency Medicine › Poisoning and overdose treatments
- Keywords
- cholinergic toxicity, cevimeline, Bacopa monnieri, herb-drug interactions, Sjögren's syndrome, herbal supplements, phosphatidylserine, muscarinic agonists, hyperhidrosis, tachycardia, cytochrome P450, drug overdose
- MeSH terms
- Cytochrome P-450 Enzyme System, Female, Humans, Middle Aged, Quinuclidines, Sjogren's Syndrome, Thiophenes, Cholinergic Agents, Bacopa
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-05, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-05 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Suspected cholinergic toxicity due to cevimeline hydrochloride and Bacopa monnieri interaction: a case report. https://app.cochat.ai/papers/10.1186/s13256-022-03479-4
- The paper
- Acquarulo, B., Tandon, P., & Macica, C. M. (2022). Suspected cholinergic toxicity due to cevimeline hydrochloride and Bacopa monnieri interaction: a case report. Journal of Medical Case Reports. https://doi.org/10.1186/s13256-022-03479-4
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.